

Radim Becvr

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7191781/radim-becvar-publications-by-citations.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

3,529
citations

13
h-index

37
g-index

37
ext. papers

5,893
ext. citations

3.4
avg, IF

6.35
L-index

#	Paper	IF	Citations
30	Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study. <i>Scientific Reports</i> , 2021 , 11, 1	4.9	2785
29	Mapping and predicting mortality from systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, 1897-1905	2.4	230
28	Nailfold capillaroscopy in systemic sclerosis: data from the EULAR scleroderma trials and research (EUSTAR) database. <i>Microvascular Research</i> , 2013 , 89, 122-8	3.7	73
27	European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. <i>Annals of the Rheumatic Diseases</i> , 2001 , 60, 585-91	2.4	65
26	Heat shock protein 90 (Hsp90) inhibition targets canonical TGF- β signalling to prevent fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 1215-22	2.4	60
25	Cytokines and adhesion molecules in renal vasculitis and lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 1998 , 13, 1662-7	4.3	53
24	S100A4 amplifies TGF- β -induced fibroblast activation in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, 1748-55	2.4	34
23	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019 , 71, 1553-1570	9.5	31
22	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. <i>Annals of the Rheumatic Diseases</i> , 2020 , 79, 618-625	2.4	30
21	Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis. <i>Cytokine</i> , 2012 , 58, 165-8	4	25
20	Tribbles homologue 3 stimulates canonical TGF- β signalling to regulate fibroblast activation and tissue fibrosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 609-16	2.4	24
19	Glycosaminoglycan polysulfuric acid (GAGPS) in osteoarthritis of the knee. <i>Osteoarthritis and Cartilage</i> , 1995 , 3, 15-23	6.2	19
18	Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease. <i>Rheumatology</i> , 2015 , 54, 2273-82	3.9	14
17	Clinical correlations of potential activity markers in systemic sclerosis. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 404-12	6.5	13
16	Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. <i>Clinical Rheumatology</i> , 2012 , 31, 557-61	3.9	12
15	Prevalence of antinucleosome antibodies by enzyme-linked immunosorbent assays in patients with systemic lupus erythematosus and other autoimmune systemic diseases. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1109, 275-86	6.5	12
14	A comparison between nailfold capillaroscopy patterns in adulthood in juvenile and adult-onset systemic sclerosis: A EUSTAR exploratory study. <i>Microvascular Research</i> , 2015 , 102, 19-24	3.7	11

13	Verrucous form of chilblain lupus erythematosus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2001 , 15, 448-51	4.6	10
12	Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis. <i>Rheumatology International</i> , 2010 , 30, 1691-3	3.6	9
11	Markers of collagen metabolism in sera of patients with various rheumatic diseases. <i>Clinica Chimica Acta</i> , 1989 , 183, 243-52	6.2	6
10	Nabumetone induces less gastrointestinal mucosal changes than diclofenac retard. <i>Clinical Rheumatology</i> , 1999 , 18, 273-8	3.9	3
9	Anticollagen antibodies in patients with juvenile chronic arthritis. <i>Clinical Rheumatology</i> , 1988 , 7, 378-83	3.9	3
8	von Willebrand factor antigen and adhesive molecules in Wegener's granulomatosis and microscopic polyangiitis. <i>Clinical Rheumatology</i> , 1997 , 16, 324-5	3.9	2
7	A3.10 Plasma levels of heat shock protein 90 correlate with disease activity, lung involvement and skin fibrosis in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, A35.1-A35	2.4	1
6	A3.16 Serum S100A4 correlates with skin fibrosis, lung involvement and disease activity in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, A48.1-A48	2.4	1
5	AB0203 S100A4 Serum Levels Correlate with Disease Activity, Skin Fibrosis and Lung Involvement in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2014 , 73, 871.1-871	2.4	1
4	Inhibition of Hsp90 Counteracts the Established Experimental Dermal Fibrosis Induced by Bleomycin. <i>Biomedicine</i> , 2021 , 9,	4.8	1
3	S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 338-339	2.2	1
2	AB0632 Association between Interstitial Pulmonary Involvement and Microvasculature Changes in Systemic Sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2016 , 75, 1120.3-1120	2.4	
1	A8.3 Deficit of S100A4 Prevents Joint Destruction and Systemic Bone Loss in hTNF α Mouse Model. <i>Annals of the Rheumatic Diseases</i> , 2013 , 72, A58.1-A58	2.4	